Navigation Links
Ibrutinib continues strong showing against mantle cell lymphoma
Date:6/19/2013

HOUSTON - In a major international study led by researchers at The University of Texas MD Anderson Cancer Center, the targeted therapy ibrutinib continues to show remarkable promise for the treatment of relapsed or refractory mantle cell lymphoma (MCL).

The most recent interim findings of the 18-center Phase 2 study were published today in the New England Journal of Medicine. Previous interim findings were presented in December 2012 at the 54th American Society of Hematology Annual Meeting and Exposition.

Unprecedented results, fewer side effects

"This oral inhibitor of the Bruton's tyrosine kinase in the B-cell receptor pathway is the most important breakthrough to date in the treatment of mantle cell lymphoma," said Michael Wang, M.D., associate professor in MD Anderson's Departments of Lymphoma and Myeloma and Stem Cell Transplantation and Cellular Therapy. Wang is lead author of the trial.

"It is an oral drug, taken once a day, and its side effects are not severe. Yet it can achieve more than previous combination chemotherapy approaches. Our results constitute excellent news for our patients and patients around the world."

The ongoing trial of oral ibrutinib in patients with heavily treated relapsed or refractory MCL has maintained a response rate as high as 70 percent - better than any other single agent ever tested in the challenging disease with milder side effects than other treatments.

Targeted approach to dangerous disease

MCL is a rare and aggressive B-cell subtype of non-Hodgkin lymphoma that, according to the Leukemia and Lymphoma Society, accounts for 6 percent of non-Hodgkin cases. Despite high response rates to initial highly toxic combination-drug chemotherapy, patients often relapse.

The B-cell receptor pathway is critical in B-cell lymphoma, and Bruton's tyrosine kinase (BTK) is an essential component of this pathway. Ibrutinib targets the BTK molecule, causing cell death and decreasing cellular migration and adhesion in malignant B-cells.

In this study, patients were given 560 mg daily ibrutinib in continuous 28-day cycles until disease progressed or side effects became intolerable. To date, 111 patients have participated in the study.

Seventy-seven percent had stage 4 disease, and the median number of prior treatments was three.

Ongoing results continue to show promise

In the past six months, ibrutinib has continued to show excellent results. With a median follow-up period of 15 months:

  • Overall response rate was 68 percent
  • Complete response rate was 21 percent
  • Partial response rate 47 percent

Response and complete remission rates improved with longer duration of treatment.

Among the 75 patients who responded, median:

  • Response duration was 18 months
  • Time to response was two months
  • Progression-free survival was 14 months

Most side effects were minor and included diarrhea, fatigue, upper respiratory tract infections, nausea and rash. Grade 3 or higher effects included low white cell blood counts, anemia and diarrhea.

Next steps

Wang believes further investigation of ibrutinib as a first line therapy and in combination with other targeted therapies and traditional cytotoxic agents is essential.

"This drug, which is the safest option we have for MCL, shows unprecedented durable single agent activity," he said. "The favorable toxicity profile also implies that ibrutinib provides the opportunity for less intense and more effective regimens. The long-term impact of ibrutinib definitely warrants further clinical testing."


'/>"/>

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
2. Ibrutinib has unprecedented impact on mantle cell lymphoma
3. Secondhand smoke continues to vex children with asthma
4. U.S. Teen Pregnancy Rate Continues to Fall
5. FlowVision Continues to Add to Its Intellectual Property Portfolio
6. Use of retail medical clinics continues to grow, study finds
7. U.S. Preterm Birth Rate Continues to Drop: Report
8. Cavern Technologies Kansas City Data Center Continues Rapid Growth with Latest Data Center Expansion
9. NaphCare, Inc. Continues Partnership with Wende and Fishkill Correctional Facilities
10. Regular marijuana use by teens continues to be a concern
11. Ladybug Vapor Steam Cleaners Dealer 1-800-GO-VAPOR.com Continues 3-Year Partnership with PowerReviews
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association ... Featuring a collection of specialty vendors and unique items from across the nation, this ... health and wellness services offered by the VNA. The boutique will be open ...
(Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...
(Date:10/13/2017)... ... , ... “The Journey: From the Mountains to the Mission Field”: the story ... the Philippines. “The Journey: From the Mountains to the Mission Field” is the creation ... has taught all ages and currently teaches a class of ladies at her church, ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... IsoComforter, Inc. ... products, announced today the introduction of an innovative new design of the shoulder pad. ... so you get maximum comfort while controlling your pain while using cold therapy. By ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion to ... awards. Ranked as number one in the South Florida Business ... in Inc. 5000 yearly list, the national specialty pharmacy has ... Armando Bardisa will soon be honored by SFBJ as ... Set to receive his award in October, ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
Breaking Medicine Technology: